EPCT-10. DEBIO1347, AN ORAL FGFR INHIBITOR: RESULTS FROM A SINGLE CENTER STUDY IN RECURRENT/REFRACTORY FGFR ALTERED PEDIATRIC GLIOMAS

BACKGROUND: Oncogenic driver alterations in FGFR are present in a subset of pediatric gliomas. Debio1347 is an orally available, highly selective FGFR 1–3 inhibitor that had a favorable safety profile and encouraging preliminary clinical activity in an adult phase 1 study. METHODS: Five children wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Farouk Sait, Sameer, Gilheeney, Stephen, Bale, Tejus, Rosenblum, Marc, Haque, Sofia, Ibanez, Katarzyna, Dinkin, Marc, Vitolano, Stephanie, Dunkel, Ira, Karajannis, Matthias
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Translational/Early Phase Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168087/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.196
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars